Introduction {#s1}
============

Notch signaling is a major regulator of progenitor cell fate and differentiation during organogenesis, repair-regeneration, and cancer. In mammals, four Notch receptors (Notch1--4) and five ligands (Delta-like: Dll1, Dll3 and Dll4 and Jagged: Jag1 and Jag2) have been described. All ligands, except Dll3, are Notch activating. Signaling is triggered by ligand-receptor binding through cell-cell interactions, which leads to sequential cleavage of the Notch receptor and binding of its intracellular domain (NICD) to a CSL/RBPJk-activator complex for activation of downstream target genes, such as HEY/HES-family members ([@bib28]; [@bib4]). While different Notch receptors are known to act in a variety of biological processes, evidence from genetic studies suggest that the Notch effects are not necessarily dependent on the type of NICD but rather of NICD dosage ([@bib21]). Notably, specific Notch ligand-receptor binding in mammalian cells appears to be mostly non-selective or context-dependent.

Interestingly, systemic deletion of *Jag1, Jag2*, or *Dll4* has been shown to result in distinct phenotypes, suggesting that these ligands could mediate unique functions not entirely due to the receptor they activate ([@bib8]; [@bib6]). Indeed, Notch ligands were reported to activate distinct targets even through binding to the same Notch receptor and ligand-specific effects have been observed in multiple contexts ([@bib25]).

The Notch pathway plays a crucial role in the developing lung. When airways are still forming epithelial progenitors initiate a differentiation program that gives rise to secretory (club, goblet), multiciliated, and neuroendocrine (NE) cells. Previous studies addressing the role of Notch in the lung focused largely on central components of this pathway (Rbpjk, Pofut1, and Hes1). Disruption of Rbpjk or the o-fucosyl-transferase Pofut1 required for Notch signaling results in aberrant expansion of multiciliated and NE cells at the cost of secretory cells ([@bib32]; [@bib33]; [@bib23]). Subsequent studies showed that club cells are more sensitive to deficiency in Notch2 while Notch 1-3 receptors contribute to control the NE population in an additive manner ([@bib24]). However, it was unclear whether individual ligand families (Delta-like and Jagged) or specific ligands (Dll1, Dll4, Jag1, and Jag2) influence distinct aspects of differentiation of airway epithelial progenitors. Notably, these ligands have been reported in partially overlapping but also distinct domains in the lung ([@bib27]; [@bib18]; [@bib32]; [@bib36]; [@bib38]; [@bib22]).

Here we explored the role of ligands using single and double conditional Jagged and Delta-like null alleles targeted to epithelial progenitors from early lung development. We show remarkably distinct roles of these ligands in the developing intra- and extrapulmonary airways and in the control of the expansion and differentiation of the NE microenvironment.

Results {#s2}
=======

Jagged ligands precede the appearance of Delta-like ligands in differentiating airway progenitors {#s2-1}
-------------------------------------------------------------------------------------------------

Although the expression patterns of Jag and Dll have been reported in both epithelial and mesenchymal layers of the developing lung, specific information about their onset of expression and regional distribution in the epithelial compartment at early stages of differentiation has been scattered and not well integrated to functional studies ([@bib27]; [@bib18]; [@bib36]; [@bib24]; [@bib32]). To gain further insights into this issue we revisited the spatial and temporal pattern of expression of Notch ligands when epithelial cells are initiating commitment to different cell fates in developing airways.

By in situ hybridization (ISH) analysis none of these ligands were detectable in the airway epithelium prior to or at E11.5 (not shown). However, at around E12.0 evidence of *Jag2* epithelial signals in the developing trachea made it the first of all Notch ligands to be induced in the differentiation program of airways ([Figure 1A](#fig1){ref-type="fig"}). Expression progressed in a proximal-to-distal fashion; at E12.5 low level signals were detected in the epithelium of extrapulmonary but not intrapulmonary airways. This contrasted with the strong *Jag2* signals present in the esophageal epithelium and in neighboring vascular structures ([Figure 1B](#fig1){ref-type="fig"}). Notably, the *Jag2* detection in epithelial progenitors of the trachea and extrapulmonary airways coincided with the previously reported onset of Notch activation and appearance of the secretory cell marker *Scgb3a2* locally ([@bib9]). No epithelial *Jag1* could be detected anywhere in airways at these stages, although clearly present in vascular structures ([Figure 1C](#fig1){ref-type="fig"}). These data supported the idea of a Jag2-Notch program giving rise to secretory cell precursors as one of the earliest events initiating differentiation in airways, even preceding the appearance of pulmonary NE cells (PNEC) reported to begin only within a day later ([@bib20]; [@bib19]; [@bib26]; [@bib30]). Indeed, expression of *Ascl1*, which marks PNEC precursors, was first found \~E13-13.5 in large intrapulmonary airways and both *Dll1* and *Dll4* were then subsequently expressed in these precursors ([Figure 1E,D](#fig1){ref-type="fig"}). By E13.5-E14.5 strong *Jag2* epithelial signals were seen throughout the trachea and main bronchi, in contrast to *Jag1*, nearly undetected at these sites ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). At E14.5 NEBs and PNECs were sharply demarcated by Ascl1, and *Dll1* and *Dll4* transcripts became prominently expressed in NEBs ([Figure 1E--F](#fig1){ref-type="fig"}). This was accompanied by the appearance of clusters of cells adjacent to NEBs, collectively marked by expression of the uroplakin *Upk3a*, the cell surface stem cell (secretory) marker SSEA1, the secretoglobin Scgb3a2 and low levels of the cytochrome gene *Cyp2f2* and CC10. The pattern was consistent with the initiation of a Notch-dependent program of secretory cells in the NEB microenvironment ([@bib9] and described later).

![Jag and Dll ligands arise in distinct spatial and temporal patterns in airway epithelial progenitors undergoing cell fate commitment.\
In situ hybridization of E12-E14.5 lungs. (**A--C**) E12-E12.5: *Jag2* is the first and only Notch ligand detected in the epithelium, initially restricted to the trachea (tr) and later extending to extrapulmonary airways but not intrapulmonary large airways (bronchi: br)(B, boxed area enlarged in right panel). *Jag1 is* absent from both trachea and bronchi. Strong Jag ligand signals in blood vessels (bv) and the esophageal epithelium (es). (**D**) E13.5: Prominent epithelial *Jag2* signals still restricted to trachea and extrapulmonary bronchi; abundant *Jag1* in vascular but not in the epithelial compartment. (**E--F**) E13.5- E14.5: *Dll1* and *Dll4* signal*s* are first detected at E13.5 in epithelial cell clusters of intrapulmonary main bronchi at sites of NEB formation marked by *Ascl1* (inset) and signals become highly localized and prominent from E14.5 onward (**G**) Schematic summarizing the time and sites of Notch ligand expression throughout the developing respiratory tract epithelium. Arrows depict representative signals in airway epithelium; (\*) depicts absence or near background signal. Bars in A-F = 40 μm.](elife-50487-fig1){#fig1}

Thus, Jag and Dll ligands appear in different domains and in a sequential proximal-distal fashion during the establishment of cell fate in airway progenitors, initiating with *Jag2* in the trachea, *Jag1,* and lastly *Dll1* and *Dll4* once NEBs form in intrapulmonary airways (summary diagram [Figure 1G](#fig1){ref-type="fig"}).

Jag1 and Jag2 regulate the balance of different cell types in extra- and intrapulmonary airways {#s2-2}
-----------------------------------------------------------------------------------------------

Given the distinct timing and spatial distribution of Jag ligands described above, we reasoned that common but also non-overlapping functions were likely to exist in the distinct domains of the respiratory tract. Inactivation of Jag1 in epithelial progenitors of intrapulmonary airways undergoing branching morphogenesis using a surfactant protein-c (*Sftpc*)-*tet*-*O* system was shown to disrupt epithelial differentiation ([@bib38]), confirming the previously reported role of Notch signaling in this process ([@bib32]; [@bib23]). Although efficient, in this targeting strategy Cre-mediated recombination was restricted to intrapulmonary airways, initiating at the onset of *Sftpc* expression in secondary buds (\~E10.5). Thus, information about a putative role of Jag1 in extrapulmonary airways (trachea, main bronchi) and at stages prior to E10.5 was missing. Moreover, little was known about how Jag2 influences lung development and whether there is any functional overlap between Jag2 and Jag1. Jag2 systemic knockout animals die at birth ([@bib14]). Lastly, no information was available about compensation of Jag by other ligands during epithelial differentiation.

We used the Shh-cre line to inactivate Jag1 and Jag2 individually or in combination in early epithelial progenitors of both extrapulmonary and intrapulmonary at the onset of lung development ([@bib11]). Jag1^flox/flox^; Shh^cre/+^ (Jag1^cnull^), Jag2^flox/flox^; Shh^cre/+^ (Jag2^cnull^) and double (Jag1^cnull^; Jag2^cnull^) null mutants were analyzed at early (E14.5) and late (E18.5) stages of airway differentiation. Gross morphological analysis of the mutant lungs showed no notable macroscopic difference in size or shape (not shown). We compared the effects of Jag1 and Jag2 loss in multiciliated-secretory cell fate selection at E18.5, once differentiated cell profiles were largely established in extrapulmonary (trachea) and intrapulmonary (lung) airways. qPCR analysis of E18.5 lung homogenates showed significant changes in markers of epithelial differentiation in all mutants ([Figure 2A](#fig2){ref-type="fig"}). Expression of the secretory markers Scgb3a2 and Scgb1a1 (encoding CC10) were reduced by 86.2% (p=5×10^−12^) and 85.6% (p=0.0001), respectively in Jag1^cnull^ mutants, but only by 25.9% (p=0.015) and 34.4% (p=0.019), respectively in Jag2^cnull^ mutants. These changes were accompanied by a significant increase in Foxj1 expression in Jag1^cnull^ (183% increase, p=0.0006) but not in Jag2^cnull^ (13% reduction, p=0.501) mutants. Thus, the differentiation program of intrapulmonary airways was more severely affected in Jag1^cnull^ than in Jag2^cnull^ mutants. The predominant contribution of Jag1 to the program of secretory cell fate as represented by these markers could be clearly seen in double Jag1^cnull^; Jag2^cnull ^mice. These mutants showed Scgb3a2 and Scgb1a1 nearly abolished and an increase in Foxj1 similar to that found in Jag1^cnull^. Altogether these results indicated that airway progenitors are largely dependent on Jag ligands to initiate secretory cell differentiation.

![*Jag1* and *Jag2* collectively contribute to balance multiciliated and secretory cell fate in intrapulmonary airways.\
(**A**) qPCR analysis: markers of multiciliated (*Foxj1)* and secretory cell fate (*Scgb3a2, Scgb1a1* \[*CC10*\]) in mutant and respective control lung homogenates (n = 4 *Jag1* control, n = 3 Jag1^cnull^; n = 4 *Jag2* control; n = 4 Jag2^cnull^; n = 4 *Jag1/Jag2* control; n = 4 Jag1^cnull^; Jag2^cnull^). Decreased expression of secretory markers and increased *Foxj1* predominantly in Jag1^cnull^ and in double Jag1^cnull^; Jag2^cnull^. Graphs represent mean ± SEM. Student's t-test: differences statistically significant at \*p*\<0.05, \*\*p\<0.005, \*\*\*p\<0.005*, n.s., not significant. (**B**) Immunofluorescence of lungs from E18.5 control and Jag mutant mice showing changes in expression of Foxj1 and CC10 in intrapulmonary airways consistent with that revealed by qPCR (DAPI in gray). (**C**) Morphometric analysis: percentage of Foxj1+ cells in control and mutant intrapulmonary airways (normalized by DAPI). Significant increase in the number of Foxj1 labeled cells in Jag1^cnull^ and in Jag1^cnull^; Jag2^cnull^, but not in Jag2^cnull^ mutants. (**D**) In situ hybridization of *Jag1* in E18.5 Jag2^cnull^ showing epithelial signals in intrapulmonary airways (arrow, bronchi: br) and in blood vessels (bv). Scale bar in B = 40 μm.](elife-50487-fig2){#fig2}

Immunofluorescence of Foxj1 and CC10 in E18.5 lung sections confirmed the changes in gene expression in intrapulmonary airways revealed by qPCR and showed secretory cells less abundant in Jag1^cnull^ compared to Jag2^cnull^ mutants ([Figure 2B](#fig2){ref-type="fig"}). Interestingly, multiciliated cell fate appeared to be minimally affected in Jag2^cnull^ airways. Morphometric analysis showed no significant change in the number of Foxj1+ cells in Jag2^cnull^ airways relative to control (p=0.164), in contrast to the \~2.5 fold increase in these cells in Jag1^cnull^ mutants (p*=*4.17×10^−7^) ([Figure 2C](#fig2){ref-type="fig"}).

To search for potential reasons contributing to the more severe ciliated cell phenotype in Jag1^cnull^ compared to Jag2^cnull^ mutants we further extended our analysis of Notch ligands to later developmental stages ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Interestingly, ISH of E14.5- E18.5 WT lungs showed that *Jag2* expression in the trachea and extrapulmonary airways continued to be robust at later stages while remaining weak and scattered in intrapulmonary bronchial epithelia. By contrast, *Jag1* expression was progressively stronger in the intrapulmonary airway epithelium from E15.5 onwards and by E18.5 expression extended to the distal bronchioles. Double ISH-immunohistochemistry for Foxj1 confirmed our previous report of *Jag1* localization in multiciliated cells ([@bib32]). Thus, our data suggested that Jag1 is the predominant ligand in intrapulmonary airways mediating secretory vs. multiciliated cell fate choice during differentiation. Consequently, Jag1^cnull^ mutants were expected to display the unbalanced abundance of multiciliated cells in intrapulmonary airways compared to Jag2^cnull^ mutants. We also reasoned that in Jag2^cnull^ mutants Notch-mediated signaling by Jag1 should compensate for the loss of Jag2, preserving the balance of multiciliated vs. secretory cell differentiation in these mutants. Indeed, analysis of Jag2^cnull^ mice confirmed the presence of *Jag1* signals in the intrapulmonary airway epithelium of these mutants ([Figure 2D](#fig2){ref-type="fig"}).

IF staining of Krt5 and β-tubulin in E18.5 Jag1^cnull^; Jag2^cnull^ double mutants revealed an expansion in the population of basal progenitors and a variable but also increased population of multiciliated cells ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Single Jag1^cnull^ or Jag2^cnull^ mutants were then examined to assess the contribution of each Jag ligand to the double mutant phenotype. For morphometric analysis we first performed IF for p63 and Foxj1, which label basal and multiciliated cells, respectively, and have the advantage of displaying nuclear signals, thus facilitating quantitation. Tracheal sections from all groups at E18.5 were analyzed and the %p63+/DAPI and %Foxj1+/DAPI were estimated. This analysis revealed that Jag2^cnull^ tracheas had a significant increase in the number of prebasal cells (%p63+/DAPI) but a trend (not significant) towards an increase in the abundance of the multiciliated cell population ([Figure 2---figure supplement 1B,C](#fig2s1){ref-type="fig"}). Notably, double ISH/immunohistochemistry for *Jag2*/p63 in WT confirmed the presence of *Jag2* in prebasal cells of the developing trachea ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [@bib22]). As expected from the distinct spatial distribution of these Jag ligands, single Jag1^cnull^ tracheas had no detectable change in the number of basal cell progenitors compared to controls.

Together these data suggest that Jag ligands mediate overlapping but distinct events along the respiratory tract epithelium. In extrapulmonary airways (trachea here) Jag2 predominantly contributes to the balance of basal versus luminal cells while Jag1 controls abundance of multiciliated cells. By contrast, in intrapulmonary airways Jag1 is the predominant ligand regulating the balance of multiciliated versus club cell fate with a lesser contribution of Jag2.

Jag ligands have minimal effects in the establishment and regulation of the NE microenvironment {#s2-3}
-----------------------------------------------------------------------------------------------

Next we investigated whether Jag ligands could influence cell fate events that ultimately regulate the PNEC pool in intrapulmonary airways, regardless of its organization as NEBs or as solitary cells. Thus, we compared levels of *Ascl1* expression in homogenates of *Jag*-cnull mutant lungs at E18.5, when NEBs are already widely distributed at branch point and internodal locations. qPCR analysis showed no difference in *Ascl1* expression between controls and mutants in any of the *Jag*-deficient airways ([Figure 3A](#fig3){ref-type="fig"}). Consistent with this, immunofluorescence for Cgrp, another established marker of PNEC fate ([@bib20]), did not reveal consistent differences in expression patterns, suggestive of alterations in NEBs\' spatial distribution, size (\~8--10 PNECs per NEB control, Jag1^cnull^, Jag2^cnull^, and double Jag1^cnull^; Jag2^cnull^) or frequency in intrapulmonary airways of mutants compared to controls ([Figure 3A--D](#fig3){ref-type="fig"}). Since in our mutants *Jag* is deleted well before epithelial progenitors differentiate, we concluded that Jag-mediated Notch signaling is unlikely to be involved in the mechanisms that initiate or restrict the domains of NEB or PNEC fate. Neither NEBs nor PNECs could be identified in extrapulmonary airways (trachea) of mutants or control animals.

![Disruption of Jagged-driven Notch signaling has no detectable impact on PNEC and NEB cell fate specification or maintenance.\
(**A**) qPCR analysis of *Ascl1* in E18.5 controls, single and double Jag1^cnull^; Jag2^cnull^ mutants showing no significant difference in expression. Graph represents mean ± SEM (n = 4 *Jag1* control, n = 3 Jag1^cnull^; n = 4 *Jag2* control; n = 4 Jag2^cnull^; n = 4 *Jag1/Jag2* control; n = 4 Jag1^cnull^; Jag2^cnull^). Student's t-test was used to analyze data. Side panels: representative Cgrp immunofluorescence (IF) in controls and mutants (**B**) IF of secretory (Scgb3a2), NEB-associated SSEA1 (CC) and Cgrp (PNEC/NEB) in control and Jag mutants. (**C, D**) Preserved NEB microenvironment in E18.5 Jag1^cnull^; Jag2^cnull^ double mutants: IF showing NEBs (Cgrp) and NEB-associated CCs (SSEA1, N1ICD, CC10 ^low^) in double null mutants similar to controls (Ex. inset in D). (**E**) qPCR analysis of *Upk3a* in E18.5 control and double Jag1^cnull^; Jag2^cnull^ mutants showing nearly abolished *Upk3a* expression in mutants (n = 3 in each group). Graph: mean ± SEM; \*\*\*p\<0.0005 (**F**) ISH of *Upk3a* (left panels) and double labeled with Ascl1 (immunohistochemistry, right panels): *Upk3a* expression predominantly in NEB-associated CCs with rare signals scattered in CC elsewhere. In double Jag1^cnull^; Jag2^cnull^ mutants CCs are abolished but in the NEB microenvironment and *Upk3a* becomes restricted to those surrounding NEBs. Scale bar in A-D, F = 40 μm. Scale bar in F inset = 20 μm.](elife-50487-fig3){#fig3}

We then examined the effect of *Jag* deletion in the population of secretory progenitors tightly associated with the developing NEBs. Previous studies have shown that they arise around E14.5 immediately adjacent to Ascl1-expressing cell clusters, being distinguished from other secretory precursors collectively by their expression of *Upk3a*, SSEA1, Scgb3a2, and low levels of *Cyp2f2* and CC10 ([@bib9]; [@bib24]). Immunofluorescence of E18.5 lung sections triple-labeled with SSEA1, Scgb3a2, and Cgrp identified the typical SSEA1+ Scgb3a2+ cells around Cgrp+ clusters similarly preserved in intrapulmonary airways of Jag1^cnull^ and Jag2^cnull^ mutants ([Figure 3B--D](#fig3){ref-type="fig"}). This contrasted with the nearly absent expression of these markers outside the NEB microenvironment in Jag1^cnull^; Jag2^cnull^ mutants ([Figure 3B--C](#fig3){ref-type="fig"}, described above). Remarkably, in double Jag1^cnull^; Jag2^cnull^ airways the only population of cells expressing secretory markers was that associated with NEBs ([Figure 3C,D](#fig3){ref-type="fig"}). This NEB-associated cell population was heterogeneous in regards to expression of the markers above even in the same airway, as also observed in control lungs ([Figure 3C](#fig3){ref-type="fig"}). Notably, double Jag1^cnull^; Jag2^cnull^ showed no evidence of change in the size of this population relative to NEBs. Since these cells are crucially dependent on Notch signaling and their only source of ligand should be Dll1 and/or Dll4 from PNECs, we performed N1ICD immunofluorescence to examine the status of Notch activation locally. Strong N1ICD labeling was found selectively in the SSEA1+ NEB-associated cell populations of mutants, indistinguishable from controls ([Figure 3D](#fig3){ref-type="fig"}). Lastly, qPCR analysis of *Upk3a*, a gene marker highly enriched in NEB-associated secretory cells but that also labels scattered secretory cells of intrapulmonary airways, showed markedly decreased levels of expression in double Jag1^cnull^; Jag2^cnull^ lungs ([Figure 3E](#fig3){ref-type="fig"}). This was consistent with the dependence of *Upk3a* on Notch signaling we previously reported ([@bib9]). The similar levels of *Ascl1* and the Cgrp expression pattern we found in controls and double *Jag* mutants ([Figure 3A](#fig3){ref-type="fig"}) suggested that the NEB size and frequency in airways is not dependent on Jag ligands. Thus we reasoned that the remaining population of *Upk3a*-expressing cells in Jag1^cnull^; Jag2^cnull^ mutants was associated with NEBs and that the significant decrease in *Upk3a* seen by qPCR resulted from the loss of the *Upk3*a-expressing scattered cell population. Indeed, ISH of *Upk3a* in these mutants showed signals restricted to branch points in proximal regions of intrapulmonary airways associated with Ascl1-expressing NEBs ([Figure 3F](#fig3){ref-type="fig"}). This was further supported by the evidence of a preserved NEB-associated SSEA1 population ([Figure 3B--D](#fig3){ref-type="fig"}) and the fact that *Upk3a* requires Notch activation not present in the extensive areas devoided of Jag ligands.

Together these results suggested that Jag1 and Jag2 have overlapping but also distinct roles in the cell fate specification of respiratory lineages in extrapulmonary and intrapulmonary airways. Jag ligands, however, appear to be dispensable for activation of Notch and induction of NEB-associated secretory cells since they can utilize Dll provided by their neighboring NE cells. Moreover, our data show no evidence that Jag ligands have any impact in regulating size or frequency of NEBs.

Dll ligands control the size of the NEB microenvironment {#s2-4}
--------------------------------------------------------

Our analysis of Jag1^cnull^; Jag2^cnull^ mutants identified seemingly self-contained units comprised of Dll-expressing NEBs and immediately adjacent cells able to activate and maintain robust Jag-independent Notch signaling for local secretory differentiation. Previous studies in *Ascl1^-/-^* mice showed that these units were strictly dependent on the presence of NEBs ([@bib9]). Questions remained whether preventing NEBs from expressing Dll ligands would have any impact on the NEB microenvironment or elsewhere if Jag ligands were still expressed. Unlike *Jag1* and *Jag2*, found in largely non-overlapping spatial and temporal patterns, *Dll1* and *Dll4* are collectively expressed in a very restricted fashion to PNEC/NEBs. Given the high probability of functional overlap, we generated mouse mutants in which both Dll ligands were deleted conditionally in the developing lung epithelium. Double deletion (Dll1^cnull^; Dll4^cnull^) was achieved from early stages using a similar targeting strategy with a *Shh^cre/+^* line.

IF analysis of E14.5 lungs from control mice showed the solitary PNECs and distinct small clusters of Ascl1+ cells in the epithelium of large intrapulmonary airways (bronchi) characteristic of the NEBs. By contrast, Dll1^cnull^; Dll4^cnull^ E14.5 showed a striking expansion in the population of Ascl1+ cells ([Figure 4A](#fig4){ref-type="fig"}). Although individual Ascl1+ cell clusters could still be identified, they often seem to coalesce in large patches to form a nearly continuous layer of Ascl1+ cells. In spite of the distribution in wider domains, these cells were not found ectopically in extrapulmonary airways or in the most distal airways undergoing branching morphogenesis. The large patches of Ascl1+ cells were identified at branch points in E18.5 lungs and by then co-expressed Cgrp, indicating their continued differentiation ([Figure 4B](#fig4){ref-type="fig"}). Thus, loss of Dll ligands expanded the Ascl1+ pool of PNEC/NEB precursors and did not prevent these cells from initiating maturation. Interestingly, Ki67 staining showed no difference in labeling associated with the Ascl1-expressing cells between control and double mutants at E18.5 or E14.5 ([Figure 4C](#fig4){ref-type="fig"}). The data supported the idea that the NEB expansion found in Dll1^cnull^; Dll4^cnull^ mutants did not result from an increase in proliferation.

![Loss of Dll-driven Notch signaling results in expansion of the NEBs.\
(**A--B**) Ascl1 immunofluorescence (IF) in E14.5 control lungs (**A**) showing discrete clusters of Ascl1+ NEBs in large intrapulmonary airways (bronchi: br) in contrast to the aberrant NEB expansion in Dll1^cnull^; Dll4^cnull^ lungs. At E18.5 (**B**) NEBs at branchpoints are also enlarged in mutants compared to controls and express Cgrp (bottom panel). (**C**) Double Ki67; Ascl1 IF shows no evidence that NEB expansion results from increased proliferation at E18.5 (top) or E14.5 (bottom panel). (**D**) qPCR analysis of NE markers at E18.5: significant increase in *Ascl1* and *Cgrp* expression in double null mutants compared to controls; single mutant Dll1^cnull^ but not Dll4^cnull^ showed increased expression of *Ascl1* (n = 3 *Dll1* control, n = 5 Dll1^cnull^ for *Ascl1* and n = 4 *Dll1* control, n = 5 Dll1^cnull^ for *Cgrp*; n = 3 *Dll4* control n = 6 Dll4^cnull^ for *Ascl1* and *Cgrp*; n = 3 *Dll1/Dll4* control; n = 3 Dll1^cnull^; Dll4^cnull^ for *Ascl1* and *Cgrp*). Graphs: mean ± SEM. \*\*\*p\<0.0005; n.s., not significant by Student's t-test (**E**) Morphometric analysis of PNECs and NEBs in E14.5 control and Dll mutant lungs. Left panel: NEB size as determined by number of PNECs per NEB. Center panel: solitary PNEC per airway. Right panel: number of NEBs. *^\*^ P\<0.05, ^\*\*^ P\<0.005, ^\*\*\*^ P\<0.0005;* n.s., not significant by Student's t-test. Scale bars in A, B = 40 μm.](elife-50487-fig4){#fig4}

To assess the contribution of each of these ligands to the Dll1^cnull^; Dll4^cnull^ phenotype, we examined Dll1^cnull^ and Dll4^cnull^ individual mutants. E18.5 lungs were isolated from single and double mutants and changes in expression of *Ascl1* and *Cgrp* were analyzed by qPCR in homogenates ([Figure 4D](#fig4){ref-type="fig"}). Double *Dll* mutants showed a significant increase in these transcripts compared to controls (*Ascl1 p=*1.1×10^−6^; *Cgrp p=*5.9×10^−5^), consistent with the aberrant NE cell expansion. However, in single Dll1^cnull^ or Dll4^cnull^ lungs *Ascl1 expression* was modestly increased only in Dll1^cnull^ and *Cgrp* mRNA was not altered in either of these mutants compared to controls. The marked difference in phenotype between double and single *Dll* mutants suggested functional redundancy between Dll1 and Dll4 in controlling NEB or PNEC-associated events. To better understand these events, we performed morphometric analysis of the NE compartment in E14.5 lungs to determine the impact of Dll in the size and frequency of NEBs and PNECs ([Figure 4E](#fig4){ref-type="fig"}). Quantitation of the number of solitary PNECs in the airway epithelium showed no difference between controls and any of the single or double mutants, suggesting that Dll disruption affected primarily the NEB microenvironment. The frequency of NEBs per airway (%) was largely unaffected, although a small difference in *Dll4* mutants reached statistical significance. However, the number of PNECs per NEB was significantly increased in both the Dll1^cnull^; Dll4^cnull^ and single Dll4^cnull^ airways, indicating that the size of NEBs was dramatically altered in these mutants.

Together the data indicated that the mechanisms that restrict PNEC fate and limit expansion of NEB were severely disrupted in *Dll* mutants.

Notch signaling and NEB-associated CCs are preserved in the absence of Dll ligands {#s2-5}
----------------------------------------------------------------------------------

The strikingly preserved integrity of the NEB microenvironment of double Jag1^cnull^; Jag2^cnull^ mutants led us to hypothesize that Dll1 and Dll4 were not only necessary and sufficient to activate local Notch signaling but also endowed the unique features of the NEB-associated club cells that distinguish them from club cells elsewhere. The absence of Dll ligands in the expanded population of NEB from double *Dll* mutants provided an opportunity to examine this issue. We asked whether the robust activation of Notch signaling seen in NEB-associated club cells (CCs) of control and *Jag* double mutants was also present in Dll1^cnull^; Dll4^cnull^ mice. Double IF for Ascl1 and N1ICD in E18.5 lung sections showed strong N1ICD signals in the NE-associated CCs of mutants indistinguishable from that of controls ([Figure 5A](#fig5){ref-type="fig"}). Notably, the NEB expansion in Dll1^cnull^; Dll4^cnull^ mutants was accompanied by a respective expansion of the NEB-associated CCs. The identity of these cell populations was further confirmed by expression of Cgrp (NEB) as well as SSEA1 and low *Cyp2f2* (NEB-associated CCs). Double ISH/immunohistochemistry showed the characteristic low levels of *Cyp2f2* expression in NEB-associated cells in contrast to the strong signals outside the NEB microenvironment ([Figure 5B](#fig5){ref-type="fig"}). The aberrant expansion of the NEB-associated cells was further demonstrated by qPCR analysis of lung homogenates, which showed a significant increase in expression of *Upk3a* in Dll1^cnull^; Dll4^cnull^ mutants compared to controls ([Figure 6A](#fig6){ref-type="fig"}). Of note, we found no change in expression of markers not directly associated with the NEB microenvironment, such as *Scgb1a1* (CC10) or *Foxj1,* which suggested that the Jag ligands present in double Dll1^cnull^; Dll4^cnull^ lungs were capable of activating Notch and mediating the balance of secretory-ciliated cell differentiation ([Figure 6A](#fig6){ref-type="fig"}).

![Expansion of the NEB-associated Club cells (CC) in the absence Delta ligands.\
(**A**) Double immunofluorescence of E18.5 control and Dll1^cnull^; Dll4^cnull^ lungs: Ascl1 and Cgrp expression in control and in the abnormally expanded NEBs (dotted areas) of mutants; robust N1ICD and SSEA1 expression in NEB-associated CCs (arrowheads and brackets). (**B**) Double ISH (*Cyp2f2)*/immunohistochemistry (Ascl1) showing strong *Cyp2f2* expression (arrowheads) in cells flanking the NE microenvironment but only low signals in the NEB-associated CCs (asterisks) of both control and Dll1^cnull^; Dll4^cnull^ mutants. Note reciprocal high (arrowhead) and low (\*) intensity of signals in areas inside and outside the NEB microenvironment. Scale bars in A = 20 μm.](elife-50487-fig5){#fig5}

![Expansion of the *Upk3a* expression domain in Dll1^cnull^; Dll4^cnull^ lungs.\
(**A**) qPCR analysis: significantly increased expression of *Upk3a*, but not of *Scgb1a1* or *Foxj1* in mutants relative to controls (n = 3 in both groups). Graphs are mean ± SEM. Student's t-test \*p\<0.05. (**B**) ISH for *Upk3a* in E18.5 lungs showing marked expansion of the *Upk3a* expression domain (arrowheads) in intrapulmonary airways of Dll1^cnull^; Dll4^cnull^ mutants (boxed areas enlarged in the lower panels). (**C**) Double immunohistochemistry (Ascl1)/ISH (*Upk3a)* confirms that the *Upk3a+* cells (arrowheads) are NEB-associated CCs. Note reciprocal high (arrowhead) and low (\*) intensity of signals in areas outside and inside the NEB microenvironment, respectively. Scale bar in B = 40 μm.](elife-50487-fig6){#fig6}

Lastly, ISH of E18.5 lungs confirmed the marked expansion in the domain of expression of *Upk3a* in Dll1^cnull^; Dll4^cnull^ mice and their association with NEBs ([Figure 6B--C](#fig6){ref-type="fig"}). Together the data strongly suggested that, in spite of the inability to express *Dll1* and *Dll4*, key features of the NEB microenvironment are preserved in these mutants by Jag ligand activation of Notch signaling.

Discussion {#s3}
==========

Here we provide evidence for distinct roles of Notch ligands once epithelial progenitors initiate differentiation. We show that Jagged*-*driven Notch signaling differentially regulates cell type-specific programs of cell fate in a temporal and spatial fashion along the developing respiratory tract epithelium. In extrapulmonary airways (largely trachea here) we found that Jag ligands are not required to induce or maintain the fate of basal cell precursors. These precursors are known to generate luminal cells in fetal airways ([@bib37]) and we now report that double *Jag1* and *Jag2* deletion leads to a major imbalance between the basal and luminal compartments with an expansion of basal cell precursors. By contrast, loss of both Jag ligands in intrapulmonary airways had no detectable impact on the NEB microenvironment. Unexpectedly, we found that *Dll* inactivation in Dll1^cnull^; Dll4^cnull^ mutants resulted in marked expansion of NEBs and their associated secretory cells.

Our analysis of the ontogeny of Notch ligands showed that *Jag2* is expressed well before *Jag1* in the epithelium and that both *Dll1* and *Dll4* appear only after NEBs form in intrapulmonary airways. Establishment of NE vs non-NE fate is known to be associated with induction of Ascl1 and a classic mechanism of lateral inhibition involving activation of Notch-Hes1 in neighboring cells ([@bib2]; [@bib13]; [@bib7]). Interestingly, although Ascl1-labeled NE precursors have been reported in the embryonic lung as early as E12.5, we found no expression of *Dll* (or *Jag*) ligands by these cells prior to E13.5 ([Figure 1](#fig1){ref-type="fig"}; [@bib1]; [@bib27]; [@bib20]; [@bib19]). This was intriguing since there is evidence that Hes1 is expressed and already active early in the developing lung epithelium in spite of no evidence of ligand expression in intrapulmonary airways to activate Notch signaling nearby NE cells ([@bib32]; [@bib26]). This suggests that at these initial stages NE vs. non-NE cell fate selection is mediated by Hes1 in a Notch-independent fashion. Consistent with this, Hes1 deletion in lung epithelial progenitors at the onset of lung development (*Shh^cre/+^; Hes1^flox/flox^)* results in aberrant expansion of NEB precursors as early as E13.5 ([@bib26]). Hes1-dependency on Notch is likely established at later developmental stages and could explain why genetic inactivation of the key Notch pathway components Pofut1 or Rbpjk using the ShhCre driver (the same used to delete Hes1, above), had no apparent effect in NE abundance at early (E14.5) stages compared to the severe effects at later (E18.5) stages ([@bib32]) and not shown). Our Dll1^cnull^; Dll4^cnull^ mutants provided the first genetic proof that these ligands are crucially involved in regulating the size the NEBs, with no clear role in controlling other aspects such as the number of PNECs or NEBs per airway. By contrast, Jag ligands had no detectable influence in NEB size or abundance. Even at E14.5, when NEBs are forming along the proximal-distal axis of intrapulmonary airways, *Jag2* is still strongly expressed only at partially overlapping proximal domains such that nascent distal clusters of Ascl1+ cells arise in non-*Jag2* or non-*Jag1*-expressing areas ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

Together our data suggest a model for the role of Notch ligands in lung development ([Figure 7](#fig7){ref-type="fig"}) in which early, when epithelial progenitors start to differentiate, a wave of Jag-Notch activation initiating in the trachea progresses in a proximal-distal fashion to establish the balance of secretory vs. multiciliated cell fates in intrapulmonary airways. A program of NE cell fate also emerges in intrapulmonary airways and as NEB start to express Dll ligands, Dll-Notch signaling is turned on in adjacent cells to form NEB-associated CCs. Local activation of Notch signaling in these cells shelters the NEB microenvironment from the neighboring epithelium, preventing aberrant NEB expansion. This role is restricted to Dll1 and Dll4, given that *Jag1*, *Jag2* single or double mutants showed no detectable effect in the size of NEBs, NEB-associated CCs or local Notch activation. The NEB microenvironment is maintained by Dll ligands that induce Notch to maintain the local balance of NE and non-NE cell types. The relevance of a late Notch-dependent phase is underscored by the expansion of the NE domain when Dll ligands are unavailable to induce Notch to generate NE-associated CCs locally. Our observations are not in conflict with recent reports that describe aggregation of NEB by a mechanism of NE cell migration (slithering) ([@bib19]; [@bib26]; [@bib3]). Rather we envision that the cell fate specification events described above precede these migratory and cluster-forming events, or overlap at least partially with mechanisms reported here. Intriguingly, in spite of the absence of Dll ligands and having Jag1 and Jag2 as the sole ligands available, the NEB-associated CC in Dll1^cnull^; Dll4^cnull^ airways exhibited robust Notch activation and maintained the unique features of CCs in this microenvironment (strong *Upk3a*, SSEA1, and low *Cyp2f2*). This suggested that the features above do not necessarily depend on the differential activation of Notch by NE-derived Dll ligands and can result from Jag-Notch activation in the cells immediately adjacent to NEBs. We speculate that a currently unidentified cell membrane-associated component of NE cells or a short-range diffusible signal(s) emanating from NEBs modulates Notch signaling or influences the cell fate program in adjacent CCs to endow these features ([Figure 7](#fig7){ref-type="fig"}).

![Proposed model for ontogeny and function of Notch ligand families in airway epithelial progenitors.\
In all panels cells expressing Jag (1, 2) or Dll (1, 4) ligands are represented collectively; Notch activated by Jag or Dll are depicted distinctly (box, right). (**A**) Distinct spatial and temporal onset of expression of Jag and Dll in wild type differentiating airways. *Top row*: Jag expression (green dots) and Jag-Notch activation (yellow dots outlined in green) initiate in trachea/extrapulmonary airways but no Jag or Dll is present in intrapulmonary airways where NE/NEBs exist (Ascl1, blue circles). *Middle row*: Jag expression continues to advance into intrapulmonary airways in a proximal-to-distal fashion to activate Notch signaling and establish the balance of secretory vs multiciliated cell fates. In intrapulmonary airways Dll ligands are induced in NEBs (red dots outlined in blue) and Dll-Notch signaling is activated in adjacent cells to form NEB-associated club cells (CC, yellow dots outlined in red), limiting NEB expansion. *Bottom row:* As differentiation proceeds, Jag-Notch activation advances more distally and surrounds the NEB and associated CCs. (**B**) In Jag1^cnull^; Jag2^cnull^ mutants the size and composition of the NEB microenvironment in intrapulmonary airways are unaffected since Jag ligands are not required for NE specification or Dll induction. Later, the NEB microenvironment is surrounded by Jag null multiciliated cells and remains unperturbed (right). (**C**) Dll1^cnull^; Dll4^cnull^ double mutants: NE/NEB formation is initiated in intrapulmonary airways (left, compare to A). However the inability of Ascl1 cells to induce Dll ligands prevents induction of Notch-Dll signaling in surrounding undifferentiated progenitors, leading to aberrant expansion of NEBs (middle). Later, as Jag expression advances in intrapulmonary airways, Jag-Notch is activated in the progenitor cells surrounding the NEB, generating CCs and restricting its expansion (right, see Discussion).](elife-50487-fig7){#fig7}

Lastly, the strength of receptor-ligand interactions is well known to depend on post-translational modifications of Notch receptors, particularly by the family of Fringe proteins, Lunatic (Lfng), Manic (Mfng) and Radical (Rfng) ([@bib29]). Mass spectrometric analysis has demonstrated Lfng to promote Notch activation by Dll1 and decrease its activation by Jag1 ([@bib16]). Lfng is expressed in NEBs rather than in the NEB-associated CCs, which activates Notch signaling ([@bib36]; [@bib35]). This is reminiscent of the developing intestinal epithelium where Fringe is expressed in the ligand-presenting cells to promote Notch activity in the neighboring cells ([@bib15]). There is currently no evidence that these proteins influence epithelial Notch signaling in the developing lung epithelium ([@bib34]; [@bib36]; [@bib35]).

In summary our study provides novel insights into developmental mechanisms mediated by Jag/Dll/Notch in the lung. These observations could be of significance in studies of human conditions associated with aberrant expansion or differentiation of NEBs and their associated CCs. Indeed, analysis of human biopsies from normal donors and patients with pulmonary NE cell hyperplasias suggest that both the NE and NE-associated CC components are coordinately altered ([@bib10]). Further studies examining the impact of Notch ligands and downstream signals in these diseases are likely to provide important insights into their pathogenesis.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                                         Source or\                                                       Identifiers                                                                               Additional\
  (species)\                                                                                            reference                                                                                                                                                  information
  or resource                                                                                                                                                                                                                                                      
  --------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------
  Genetic reagent (*M. musculus*)   *Dll1^flox^*                                                        PMID: [16495313](https://www.ncbi.nlm.nih.gov/pubmed/16495313)   MGI: [3044907](http://www.informatics.jax.org/allele/MGI:3044907)                         Dr. Julian Lewis

  Genetic reagent (*M. musculus*)   *Dll4^flox^*                                                        PMID: [18824585](https://www.ncbi.nlm.nih.gov/pubmed/18824585)   MGI: [3828266](http://www.informatics.jax.org/allele/key/65778)                           Dr. Freddy Radtke (École polytechnique fédérale de Lausanne)

  Genetic reagent (*M. musculus*)   *Jag1^flox^*                                                        PMID: [16495313](https://www.ncbi.nlm.nih.gov/pubmed/16495313)   MGI: [3623344](http://www.informatics.jax.org/allele/key/42790)                           Dr. Julian Lewis

  Genetic reagent (*M. musculus*)   *Jag2^flox^*                                                        PMID: [20533406](https://www.ncbi.nlm.nih.gov/pubmed/20533406)   MGI: [4829504](http://www.informatics.jax.org/allele/key/618622)                          Dr. Thomas Gridley (Tufts University)

  Genetic reagent (*M. musculus*)   *Shh^cre^*                                                          Jackson Laboratory                                               Stock\# 005622, RRID: [IMSR_JAX:005622](https://scicrunch.org/resolver/IMSR_JAX:005622)   PMID: [15315763](https://www.ncbi.nlm.nih.gov/pubmed/15315763)

  Antibody                          anti-beta IV tubulin (mouse monoclonal)                             Abcam                                                            Cat\#ab11315,\                                                                            IF (1:100)
                                                                                                                                                                         RRID:[AB_297919](https://scicrunch.org/resolver/AB_297919)                                

  Antibody                          anti-Ascl1 (mouse monoclonal)                                       Thermo Fisher Scientific                                         Cat\# 14-5794-82,\                                                                        IHC/IF (1:100), IF requires tyramide amplification
                                                                                                                                                                         RRID: [AB_2572887](https://scicrunch.org/resolver/AB_2572887)                             

  Antibody                          anti-CC10 (goat polyclonal)                                         Santa Cruz Biotechnology                                         Cat\# sc-9772, RRID: [AB_2238819](https://scicrunch.org/resolver/AB_2238819)              IF (1:150)

  Antibody                          anti-Cgrp (rabbit polyclonal)                                       Sigma-Aldrich                                                    Cat\# C8198, RRID: [AB_259091](https://scicrunch.org/resolver/AB_259091)                  IF (1:2500)

  Antibody                          anti-Foxj1 (mouse monoclonal)                                       Thermo Fisher Scientific                                         Cat\# 14-9965-82,\                                                                        IHC/IF (1:50)
                                                                                                                                                                         RRID: [AB_1548836](https://scicrunch.org/resolver/AB_1548836)                             

  Antibody                          anti-Ki67 (rabbit monoclonal)                                       Cell Signaling Technology                                        Cat \# 9129,\                                                                             IF (1:100)
                                                                                                                                                                         RRID: [AB_2687446](https://scicrunch.org/resolver/AB_2687446)                             

  Antibody                          anti-Krt5 (rabbit polyclonal)                                       Biolegend                                                        Cat\# 905501,\                                                                            IF (1:500)
                                                                                                                                                                         RRID: [AB_2565050](https://scicrunch.org/resolver/AB_2565050)                             

  Antibody                          anti-Krt8 (chicken polyclonal)                                      Abcam                                                            Cat\# ab107115,\                                                                          IF (1:500)
                                                                                                                                                                         RRID: [AB_10976462](https://scicrunch.org/resolver/AB_10976462)                           

  Antibody                          anti-N1ICD (rabbit monoclonal)                                      Cell Signaling Technology                                        Cat\# 4147,\                                                                              IF (1:100), requires tyramide amplification
                                                                                                                                                                         RRID: [AB_2153348](https://scicrunch.org/resolver/AB_2153348)                             

  Antibody                          anti-p63 (rabbit polyclonal)                                        Santa Cruz Biotechnology                                         Cat\# sc8343, RRID: [AB_653763](https://scicrunch.org/resolver/AB_653763)                 IHC/IF (1:400)

  Antibody                          anti-Scgb3a2\                                                       R and D Systems                                                  Cat\# AF3465, RRID: [AB_2183550](https://scicrunch.org/resolver/AB_2183550)               IF (1:100)
                                    (goat polyclonal)                                                                                                                                                                                                              

  Antibody                          anti-SSEA1\                                                         EMD Millipore                                                    Cat\# MAB4301, RRID: [AB_177627](https://scicrunch.org/resolver/AB_177627)                IF (1:300)
                                    (mouse monoclonal)                                                                                                                                                                                                             

  Antibody                          anti-rabbit, Alexa Fluor 488 (donkey polyclonal)                    Thermo Fisher Scientific                                         Cat\# A21206, RRID: [AB_2535792](https://scicrunch.org/resolver/AB_2535792)               IF (1:300)

  Antibody                          anti-rabbit, Alexa Fluor 568 (donkey polyclonal)                    Thermo Fisher Scientific                                         Cat\# A10042, RRID: [AB_2534017](https://scicrunch.org/resolver/AB_2534017)               IF (1:300)

  Antibody                          anti-rabbit, Alexa Fluor 647 (donkey polyclonal)                    Thermo Fisher Scientific                                         Cat\# A31573,\                                                                            IF (1:300)
                                                                                                                                                                         RRID: [AB_2536183](https://scicrunch.org/resolver/AB_2536183)                             

  Antibody                          anti-goat, Alexa Fluor 488 (donkey polyclonal)                      Thermo Fisher Scientific                                         Cat\# A11055, RRID: [AB_2534102](https://scicrunch.org/resolver/AB_2534102)               IF (1:300)

  Antibody                          anti-goat, Alexa Fluor 568 (donkey polyclonal)                      Thermo Fisher Scientific                                         Cat\# A11057, RRID: [AB_2534104](https://scicrunch.org/resolver/AB_2534104)               IF (1:300)

  Antibody                          anti-goat, Alexa Fluor 647 (donkey polyclonal)                      Thermo Fisher Scientific                                         Cat\# A21447, RRID: [AB_2535864](https://scicrunch.org/resolver/AB_2535864)               IF (1:300)

  Antibody                          anti-chicken,\                                                      Jackson ImmunoResearch                                           Cat\# 703-545-155, RRID: [AB_2340375](https://scicrunch.org/resolver/AB_2340375)          IF (1:300)
                                    Alexa Fluor 488 (donkey polyclonal)                                                                                                                                                                                            

  Chemical compound, drug           BM-Purple                                                           Roche                                                            Cat\# 11442074001                                                                         

  Commercial assay, kit             anti-Mouse IgG (Peroxidase) polymer detection kit, made in horse    Vector Laboratories                                              Cat\# MP-7402, RRID: [AB_2336528](https://scicrunch.org/resolver/AB_2336528)              

  Commercial assay, kit             anti-Rabbit IgG (Peroxidase) polymer detection kit, made in horse   Vector Laboratories                                              Cat\# MP-7401, RRID: [AB_2336529](https://scicrunch.org/resolver/AB_2336529)              

  Commercial assay, kit             TSA Plus Cyanine 3                                                  Akoya Biosciences                                                Cat\# NEL753001KT                                                                         Previously PerkinElmer

  Commercial assay, kit             TSA Plus Cyanine 5                                                  Akoya Biosciences                                                Cat\# NEL745001K                                                                          Previously PerkinElmer

  Commercial assay, kit             ImmPACT DAB peroxidase (HRP) substrate                              Vector Laboratories                                              Cat\# SK-4105, RRID: [AB_2336520](https://scicrunch.org/resolver/AB_2336520)              

  Commercial assay, kit             RNeasy mini kit                                                     Qiagen                                                           Cat\# 74104                                                                               

  Commercial assay, kit             MAXIscript T7                                                       Thermo Fisher Scientific                                         Cat\# AM1314M                                                                             

  Commercial assay, kit             SuperScript IV First-Strand Synthesis System                        Thermo Fisher Scientific                                         Cat\# 18091050                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mouse models {#s4-1}
------------

*Dll1^flox/flox^* and *Jag1^flox/flox^* mice were provided by Dr. Julian Lewis ([@bib12]; [@bib5]). Dll1^cnull^ mice were generated by crossing *Dll1^flox/flox^* female mice with *Dll1^flox/+^; Shh^cre/+^* males. *Dll4^flox/flox^* mice were obtained from Dr. Freddy Radtke ([@bib17]). Dll4^cnull^ mice were generated by crossing *Dll4^flox/flox^* female mice with *Dll4^flox/+^; Shh^cre/+^* males. Dll1^cnull^; Dll4^cnull^ mice were generated by crossing *Dll1^flox/flox^; Dll4^flox/flox^* females with *Dll1^flox/+^; Dll4^flox/+^; Shh^cre/+^* males. Jag1^cnull^ mice were generated by crossing *Jag1^flox/flox^* females with *Jag1^flox/+^; Shh^cre/+^* males. *Jag2^flox/flox^* mice were provided by Dr. Thomas Gridley ([@bib36]). Jag2^cnull^ mice were generated by crossing *Jag2^flox/flox^* females with *Jag2^flox/+^; Shh^Cre/+^* males. Jag1^cnull^; Jag2^cnull^ mice were generated by crossing *Jag1^flox/flox^; Jag2^flox/flox^* females with *Jag1^flox/+^; Jag2^flox/+^; Shh^cre/+^* males. Embryos were harvested at E14.5 and E18.5, where day 0.5 was counted as the morning when a vaginal plug was found. All experiments involving animals were performed in accordance with the protocols approved by Columbia University Medical Center.

Immunofluorescence {#s4-2}
------------------

Whole lung and trachea were harvested from mice at E14.5 and E18.5 and fixed in 4% paraformaldehyde at 4°C overnight. Samples then underwent PBS washes and 15% and 30% sucrose washes before embedding in OCT. Samples were incubated with primary antibodies (overnight at 4°C) and secondary antibodies conjugated with Alexa488, 568, or 647 (1:300) with NucBlue Fixed Cell ReadyProbes Reagent (DAPI) (Thermo Fisher \#R37606) for 45 min. After washing, samples were mounted with ProLong Gold antifade reagent for analysis. When necessary, heat-induced epitope retrieval was performed using citric acid-based antigen unmasking solution (Vector Laboratories \#H-3300). Ascl1 and N1ICD staining required tyramide amplification (cyanine 3 or cyanine 5) used with horse radish peroxidase conjugation (species-specific ImmPRESS kit, Vector Laboratories). Antibodies used were: anti-β-tubulin IV (Abcam \#ab11315, 1:100), anti-Ascl1 (Thermo Fisher \#14-5794-82, 1:100), anti-CC10 (Santa Cruz sc9772, 1:150), anti-Cgrp (Sigma Aldrich \#C8198, 1:2500), anti-Foxj1 (Thermo Fisher \#14-9965-80, 1:50), anti-Ki67 (Cell Signaling \#9129, 1:100), anti-Krt5 (Biolegend \#905501, 1:500), anti-Krt8 (Abcam \#ab107115, 1:500); anti-N1ICD (Cell Signaling \#4147, 1:100), anti-p63 (Santa Cruz \#sc8343, 1:400), anti-Scgb3a2 (R and D Systems \#AF3465, 1:100), anti-SSEA1 (EMD Millipore \#MAB4301, 1:300). Images were acquired using a Leica DMi8 microscope or Zeiss LSM710 confocal laser scanning microscope.

Morphometric analysis {#s4-3}
---------------------

To determine the percentage of Foxj1+ ciliated cells in control and *Jag-*cnull mutant intrapulmonary airways E18.5 coronal sections of whole lungs were stained with Foxj1 and DAPI. Two sections from two separate embryos for each genotype were used for counting. DAPI+ epithelial cells were counted in intrapulmonary airways and were compared to the number of Foxj1+ cells to determine Foxj1+ percentages.

To determine the percentage of Foxj1+ ciliated cells in control and *Jag-*cnull mutant tracheas E18.5 coronal sections of whole tracheas were stained with Foxj1 and DAPI. Two sections of whole trachea from one embryo for each genotype were used for counting. DAPI+ epithelial cells were counted in one side of the trachea and were compared to the number of Foxj1+ cells to determine Foxj1+ percentages.

Analysis of neuroendocrine cells and neuroepithelial bodies (NEBs) was performed on E14.5 *Delta-*cnull mutants. Sections were stained with Ascl1 and DAPI. Three sections from three separate embryos for each genotype were used for counting. For each section the number of intrapulmonary airways was counted, as well as the number of NEBs and solitary neuroendocrine cells. The ratios of NEBs/airway and solitary neuroendocrine cells/airway were calculated. Additionally, NEB size was examined. In each section, NEB size was determined by counting the number of neuroendocrine cells in contact with each other, where an NEB was determined to be a group of three or more cells.

In situ hybridization {#s4-4}
---------------------

Frozen sections were processed as described for immunofluorescence. In situ hybridization was performed using digoxigenin-UTP-labeled probes as previously described ([@bib31]; [@bib32]; [@bib9]). Probes are listed in [Table 1](#table1){ref-type="table"}. Hybridization probes were ordered from Integrated DNA Technologies at 25 nM with standard desalting and stored as 100 µM stocks in DEPC-treated water.

###### Primers used to generate ISH probes.

T7 or T3 primers were added to the reverse or forward primers of each gene, respectively.

  Gene       Forward (5' → 3')                              Reverse (5' → 3')
  ---------- ---------------------------------------------- ---------------------------------------------
  *Dll1*     AATTAACCCTCACTAAAGGGAGACTGCTGAGAGAGGAAGGGAG    TAATACGACTCACTATAGGGAGAAGACCCGAAGTGCCTTTGTA
  *Dll4*     AATTAACCCTCACTAAAGGGAGACTACTCAGACACCCAGCTCC    TAATACGACTCACTATAGGGAGAATCCTTTGCAAGCCTCCTCT
  *Jag1*     AATTAACCCTCACTAAAGGGAGACGCCATAGGTAGAGTTTGAGG   TAATACGACTCACTATAGGGAGATAGTTGCTGTGGTTCTGAGC
  *Jag2*     AATTAACCCTCACTAAAGGGAGATGGCACCCAGAACCCTTG      TAATACGACTCACTATAGGGAGAATACTCCGTTGTTTTCCGCC
  *Ascl1*    AATTAACCCTCACTAAAGGGTCGTCCTCTCCGGAACTGAT       TAATACGACTCACTATAGGGAGAAGAAGCAAAGACCGTGGGAG
  *Upk3a*    AATTAACCCTCACTAAAGGGGTGGCTGGACTGTGAACCTC       TAATACGACTCACTATAGGGTTGCCCACCCTGACTAGGTA
  *Cyp2f2*   AATTAACCCTCACTAAAGGGGGAACTTTGGAGGCATGAAA       TAATACGACTCACTATAGGGAACTCCTGAGGCGTCTTGAA

Quantitative real-time PCR {#s4-5}
--------------------------

Quantitate real-time PCR was performed as previously described ([@bib32]). RNA was extracted using the RNeasy kit (Qiagen) and reverse transcribed using Oligo(DT) primers (SuperScript III or IV kits, Thermo Fisher). The following primers (Thermo Fisher) were used: Ascl1 (Mm03058063_m1), Cgrp (Mm00801463_g1), Foxj1 (Mm01267279_m1), Scgb1a1/CC10 (Mm00442046_m1), Scgb3a2 (Mm00504412_m1), Upk3a (Mm00452321_m1). Reactions were performed using Taq-Man Advanced Master Mix (Thermo Fisher \#4444556) using β-actin as internal control and a Step-One Plus Instrument (Applied Biosystems). ΔΔCT method was used to calculate changes in expression levels.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Jagged and Delta ligands control distinct events during airway progenitor cell differentiation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Reviewing Editor and Didier Stainier as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

All of the reviewers found your study to be insightful and important. Reviewer 1 had concerns regarding some of the interpretations of the role of the Jagged ligands which may require some additional experimentation. Moreover, reviewers 2 and 3 had concerns on the timing and quantitative nature of the roles for Jagged and Delta ligands which may also require additional experiments to address. The additional experimentation should be well within the authors abilities. Please also revise the text to address the noted grammatical issues.

*Reviewer \#1:*

This is an interesting report from a group that has been at the forefront of exploring the role of Notch signaling in airway development. The authors have provided evidence of a divergence in the role of specific Notch ligands with Jag ligands regulating the balance of luminal cell development whereas delta ligands regulating neuroendocrine cell development. There are a few things that need to be done to strengthen the report:

1\) The data in Figure 3 showing that loss of Jag1/Jag2 is a bit confusing at least how it is described. The authors state that there is little to no effect of these 2 ligands on NEB formation. Yet their data show a strong decrease in *Upk3a* expression and their ISH shows what appears to be a reduction in the number of NEBs. The authors should clarify whether loss of Jag1/Jag2 lead to a quantitative loss of NEBs and what this means in the context of differential Notch ligand usage in lung development.

2\) The data in Figure 4 and Figure 5 showing expansion of NEBs upon loss of Dll1/Dll4 are a bit confusing. Do the authors think this is really an expansion of NEBs or could it be a reprogramming of airway epithelium into a neuroendocrine fate rather than secretory or ciliated? It is difficult to tell in the pictures provided. This is an important comparison as it could lead to an even more interesting result.

3\) The *Upk3a* staining in Figure 5C is not very convincing. It needs to be improved upon or another technique used (i.e. RNAscope) to really define the differences between WT and Dll1/Dll4 knockouts.

4\) There are numerous grammatical errors throughout the manuscript that should be corrected.

*Reviewer \#2:*

This is an interesting article that explores roles for various Notch ligands in the regulation of epithelial cell fate in the developing mouse lung. These studies build upon a fairly extensive literature published by these and other authors. This is important work but even though the presented data are of good quality, conclusions seem overstated and data raise unexplained questions that should be addressed with additional experimental analysis and/or discussion. The following concerns were noted:

1\) Figure 1. Data presented in Figure 1 show in situ localization of Jag1, Jag2, Dll1 and Dll4 mRNA within embryonic mouse lungs at either E12, 12.5 or E13.5 (Jag1 and Jag 2) or E13.5 and E14.5. Even though these data provide information regarding spatial distribution of these ligands, it does not adequately address differences in the temporal expression pattern that the authors suggest represents an important distinction between these Notch ligands. As such, conclusions such as those made in multiple statements such as \"Analyses of the ontogeny of these ligands showed that Jag2 is expressed well before all others and that Dll ligands appear last.....\" are not supported by data presented in this manuscript. If temporal/spatial expression data are fragmented and spread across a number of other manuscripts in the existing literature, it would be helpful to cite these papers and perhaps present a comprehensive analysis in this manuscript.

2\) Results from Figure 1 and Figure 2 present a rather confusing picture that most likely results from the fact that experiments in Figure 1 only evaluate Jag ligand expression from E12-E14.5 yet results of *Shh*-cre mediated loss-of-function are evaluated at E18.5. A more comprehensive presentation of spatial/temporal expression in Figure 1 would allow readers to better appreciate why Jag2-lof has minimal impact on lung development compared to Jag1-lof (which according to data in Figure 1 is only expressed within developing lung vasculature and not endoderm)?

3\) Related to concerns above, the authors conclude that \"We propose that Jag1-Notch mediated signaling compensates for the loss of Jag2, preserving most of the secretory cell population in these mutants\". However, no data are shown regarding Jag1 expression in either later stages of normal developing lung or following Jag2-lof.

4\) Figure 1---figure supplement 2 -- title states that NEB\'s appear in \"non-Jag2 expressing\" domains. In fact, the data suggest that appearance of NEB\'s occurs independently of Jag2 expression as neither presence nor absence of Jag2 mRNA impacts presence of clusters of Ascl1-expressing cells.

5\) The Discussion section is written in a rather cryptic style that is difficult to read. For example, the statement \"While our findings are not in conflict with the reported role of Hes1-Ascl1 in NE-non-NE cell fate choice, they strongly suggest that this mechanism occurs in a Notch-independent fashion.\" is not adequately discussed. Please reference the article being referred to and also explain why their data strongly suggest that this mechanism occurs in a Notch-independent fashion. Perhaps related to this, an interesting but unresolved observation in the current study is that it appears that even though Dll ligands activate Notch signaling in variant club cells that limit expansion of NEB\'s, this occurs despite the persistence of N1ICD immunoreactivity within this population. What about other Notch receptors? Is it possible that N1ICD results from Jag signaling? Further discussion and possibly experimental analysis would be of value in clarifying these issues for the reader.

6\) The statement \"These mechanisms likely contribute to the pathogenesis of human conditions resulting from aberrant lung differentiation, including NE hyperplasias and cancer\" are not supported by data and seem rather speculative.

*Reviewer \#3:*

This paper determines the specific roles of Notch ligand family of genes in airway epithelial fate determination during lung development. The authors showed that Dll and Jag start to express in different temporal and spatial manner. While Jag1 and Jag2 are crucial for multiciliated cell differentiation in the lung and basal cell and multiciliated cell differentiation in the trachea, loss of Dll1 and Dll4 led to expansion of PNECs. The authors also assayed the molecular characteristics of the NEB-associated club cells in both Dll^cnull^ and Jag^cnull^ mutants, providing a novel insight into their initiation. Overall, this manuscript presents a systemic characterization of the distinct functions of Jag/Dll/Notch in lung epithelium, and should raise broad interest.

Specific points:

\- What may be the reason that loss of Jag1, but not Jag2, led to significant multiciliated cell phenotype, given the fact that Jag2 is the predominant Notch ligand in the extrapulmonary airway by in situ? qRT would be informative of the level.

\- What may be the reason behind the role of Jag1 in ciliated cells, and Jag2 in basal cells? Temporal expression of Jag1, Jag2 at E15.5-16.5 would be informative.

\- A close analysis of Jag expression in the NEB microenvironment in the Dll mutant will be informative.

\- Subsection "DLL ligands control the size and of the NEB microenvironment": \"Interestingly, Ki67 staining....... in proliferation\" is based on data at E18.5. Ki67 staining at earlier stage (e.g. E14.5) would further support the conclusion.

\- Is there any alveolar phenotype in any of the mutants?

10.7554/eLife.50487.sa2

Author response

> Reviewer \#1:
>
> 1\) The data in Figure 3 showing that loss of Jag1/Jag2 is a bit confusing at least how it is described. The authors state that there is little to no effect of these 2 ligands on NEB formation. Yet their data show a strong decrease in Upk3a expression and their ISH shows what appears to be a reduction in the number of NEBs. The authors should clarify whether loss of Jag1/Jag2 lead to a quantitative loss of NEBs and what this means in the context of differential Notch ligand usage in lung development.

Indeed, we have not emphasized in our text that the *Upk3a* expression depicted in Figure 3E by qPCR analysis in whole lungs included *Upk3a* expression from NEB-associated CCs and the multiple small foci of *Upk3a* scattered in airways. Since Ascl1 qPCR analysis in the same samples and IF for Cgrp confirmed that NEB population was equally preserved in control and double Jag mutants (Figure 3A), the significant decrease in *Upk3a* was unlikely due to the loss of the NEB-associated CCs but rather resulted from the loss of the *Upk3a*-expressing scattered cell population. This was further supported by the evidence of preserved NEB-associated SSEA1 population (Figure 3B-D) and the fact that *Upk3a* requires Notch activation not present in the extensive areas devoid of Jag ligands. These explanations have been added in the current revised version.

> 2\) The data in Figure 4 and Figure 5 showing expansion of NEBs upon loss of Dll1/Dll4 are a bit confusing. Do the authors think this is really an expansion of NEBs or could it be a reprogramming of airway epithelium into a neuroendocrine fate rather than secretory or ciliated? It is difficult to tell in the pictures provided. This is an important comparison as it could lead to an even more interesting result.

Given the expanded domains of expression of NEB and NEB-associated markers without evidence of increased proliferation, we ascribed these changes to the activation of an aberrant differentiation program in which NEB expansion was no longer restricted by Dll induction of Notch signaling in adjacent cells. This restriction occurred only later, when the expanded NEB was surrounded by Jag-Notch activation (independent of Dll). We do not believe that this results from reprograming (switch in cell fate) but rather the induction of an aberrant program of cell fate selection. We have commented on these issues in the revised Discussion section.

> 3\) The Upk3a staining in Figure 5C is not very convincing. It needs to be improved upon or another technique used (i.e. RNAscope) to really define the differences between WT and Dll1/Dll4 knockouts.

We now provide new additional evidence of major expansion in the *Upk3a* domain of Dll1^cnull^; Dll4^cnull^ mutants (new Figure 6B).

> 4\) There are numerous grammatical errors throughout the manuscript that should be corrected.

We have edited the text extensively to address this issue.

> Reviewer \#2:
>
> 1\) Figure 1. Data presented in Figure 1 show in situ localization of Jag1, Jag2, Dll1 and Dll4 mRNA within embryonic mouse lungs at either E12, 12.5 or E13.5 (Jag1 and Jag 2) or E13.5 and E14.5. Even though these data provide information regarding spatial distribution of these ligands, it does not adequately address differences in the temporal expression pattern that the authors suggest represents an important distinction between these Notch ligands. As such, conclusions such as those made in multiple statements such as \"Analyses of the ontogeny of these ligands showed that Jag2 is expressed well before all others and that Dll ligands appear last.....\" are not supported by data presented in this manuscript. If temporal/spatial expression data are fragmented and spread across a number of other manuscripts in the existing literature, it would be helpful to cite these papers and perhaps present a comprehensive analysis in this manuscript.

As pointed out by the reviewer, other papers, including some from our lab, have already reported the Jag and Dll ligand expression patterns in the developing lung at late developmental stages. We focused on the relatively less explored early stages of lung development and initially did not include stages already reported. However, we agree that, as presented, the information seemed fragmented and difficult to interpret. Thus, in our revised manuscript we now provide a more comprehensive expression pattern analysis with stages ranging from E12-E18.5. We also include a diagram that summarizes the timing and spatial distribution in the respiratory epithelium (revised Figure 1 and Figure 1---figure supplement 1).

> 2\) Results from Figure 1 and Figure 2 present a rather confusing picture that most likely results from the fact that experiments in Figure 1 only evaluate Jag ligand expression from E12-E14.5 yet results of Shh-cre mediated loss-of-function are evaluated at E18.5. A more comprehensive presentation of spatial/temporal expression in Figure 1 would allow readers to better appreciate why Jag2-lof has minimal impact on lung development compared to Jag1-lof (which according to data in Figure 1 is only expressed within developing lung vasculature and not endoderm)?

As described above, in our revised manuscript we now provide a comprehensive expression pattern analysis (E12-E18.5) of ligands and a summary diagram. Indeed, these show more clearly that the Jag1 is the predominant ligand in intrapulmonary airways, explaining the differences in phenotype between the Jag mutants.

> 3\) Related to concerns above, the authors conclude that \"We propose that Jag1-Notch mediated signaling compensates for the loss of Jag2, preserving most of the secretory cell population in these mutants\". However, no data are shown regarding Jag1 expression in either later stages of normal developing lung or following Jag2-lof.

To address this criticism we now include Jag ligand expression analysis at later stages (revised Figure 1---figure supplement 1) and show that Jag1 expression is extensively expressed in intrapulmonary airways, only partially overlapping with Jag2. We also show expression of Jag1 in the airway epithelium of Jag2^cnull^ mice (new Figure 2). These support the idea that Jag1 maintains Notch signaling in intrapulmonary airways as an attempt to preserve the secretory cell population in Jag2 mutants. We have commented on these observations in the revised text.

> 4\) Figure 1---figure supplement 2 -- title states that NEB\'s appear in \"non-Jag2 expressing\" domains. In fact, the data suggest that appearance of NEB\'s occurs independently of Jag2 expression as neither presence nor absence of Jag2 mRNA impacts presence of clusters of Ascl1-expressing cells.

The reviewer is correct. However, we included this picture rather to illustrate the discrepancy between sites of Jag2 and Ascl1 expression along the proximal-distal axis of intrapulmonary airway as NEBs form more distally.

> 5\) The Discussion section is written in a rather cryptic style that is difficult to read. For example, the statement \"While our findings are not in conflict with the reported role of Hes1-Ascl1 in NE-non-NE cell fate choice, they strongly suggest that this mechanism occurs in a Notch-independent fashion.\" is not adequately discussed. Please reference the article being referred to and also explain why their data strongly suggest that this mechanism occurs in a Notch-independent fashion.

We have revised the text extensively and discuss in more detail the Notch-independent mechanism proposed.

> Perhaps related to this, an interesting but unresolved observation in the current study is that it appears that even though Dll ligands activate Notch signaling in variant club cells that limit expansion of NEB\'s, this occurs despite the persistence of N1ICD immunoreactivity within this population. What about other Notch receptors? Is it possible that N1ICD results from Jag signaling? Further discussion and possibly experimental analysis would be of value in clarifying these issues for the reader.

We would like to stress that the inability of Dll mutants to limit NEB expansion is an early event that results from the failure to activate Dll-mediated Notch signaling locally. Indeed, in Dll1^cnull^; Dll4^cnull^ mutants the expanded NEBs are later surrounded by club cells that express NICD as a result of a proximal-distal "wave" of Jag-activation of Notch signaling for secretory-ciliated cell fate selection in airway progenitor cells. These ideas and model are presented in Figure 7 ("Later, Jag ligands in intrapulmonary airways activate Notch signaling in progenitor cells surrounding the NEB and generate typical NEB-associated CCs"). Other Notch receptors besides N1ICD are likely involved in these events as shown by genetic studies in which Notch1-3 were sequentially inactivated in the developing lung (Morimoto et al., 2012). We did not explore further the role of Notch receptors as we considered it be beyond of the scope of the present work.

> 6\) The statement \"These mechanisms likely contribute to the pathogenesis of human conditions resulting from aberrant lung differentiation, including NE hyperplasias and cancer\" are not supported by data and seem rather speculative.

We agree and have edited the abstract and discussion to address this issue.

> Reviewer \#3:
>
> \- What may be the reason that loss of Jag1, but not Jag2, led to significant multiciliated cell phenotype, given the fact that Jag2 is the predominant Notch ligand in the extrapulmonary airway by in situ? qRT would be informative of the level.

Our data is consistent with the reviewer's idea that this is due to the predominant expression of Jag1 in intrapulmonary airways mediating secretory vs ciliated cell fate choice. Thus, Jag1 mutants have unbalanced excessive abundance of ciliated cells at the costs of secretory cells in intrapulmonary airways. The differences in Jag patterns of expression are now more clearly depicted in current Figure 1---figure supplement 1.

> \- What may be the reason behind the role of Jag1 in ciliated cells, and Jag2 in basal cells? Temporal expression of Jag1, Jag2 at E15.5-16.5 would be informative.

Similarly, as above, this could be attributed to differences in the spatial distribution of the Jag ligands. Jag 1 is essentially expressed in intrapulmonary airways, which do not contain basal cells. By contrast Jag2 is prominent in the tracheal epithelium from the earliest stages, where basal cell precursors undergo differentiation. We have included Jag2 expression in E15.5-E16.5, as requested, and show Jag2 co-localization with the basal cell marker p63 (Figure 1---figure supplement 1C; Jag1 is not expressed in trachea).

> \- A close analysis of Jag expression in the NEB microenvironment in the Dll mutant will be informative.

Previous studies from our lab and from our colleagues, as well as data from our current analysis showed Jag ligand expression, mostly Jag1, throughout the epithelium of intrapulmonary airways, including the regions immediately flanking the NEB microenvironment (Tsao et al., 2009; Xu et al., 2009; Figure 1---figure supplement 1, Figure 1---figure supplement 2). Moreover, we had evidence that Dll1^cnull^; Dll4^cnull^ mutants have a normal balance of secretory-ciliated cells in intrapulmonary airways, as seen by analysis of markers of differentiation that are largely dependent on normal Jag-Notch signaling (Figure 6A: Scgb1a1, Foxj1). These observations leave Jag as the only ligands acting in Dll1^cnull^; Dll4^cnull^ mutants to mediate Notch-related events nearby and away from the NEB microenvironment.

> \- Subsection "DLL ligands control the size and of the NEB microenvironment": \"Interestingly, Ki67 staining....... in proliferation\" is based on data at E18.5. Ki67 staining at earlier stage (e.g. E14.5) would further support the conclusion.

As requested, we have performed Ki67 staining in double E14.5 Dll null mutants and confirmed our previous conclusion that cell proliferation is not increased in the areas of expanded NEBs (current Figure 4C).

> \- Is there any alveolar phenotype in any of the mutants?

We have limited our study to prenatal stages (prior to alveolar development) largely due to neonatal lethality. Our analysis of E18.5 mutants did not detect obvious changes in sacculation or distal differentiation.
